The E3 ligase TRAF4 promotes IGF signaling by mediating atypical ubiquitination of IRS-1

被引:0
作者
Yu W. [1 ]
Singh R. [2 ]
Wang Z. [1 ,2 ]
O'Malley B.W. [2 ]
Yi P. [2 ]
机构
[1] Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX
[2] Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
来源
Yi, Ping (pyi@bcm.edu) | 1600年 / American Society for Biochemistry and Molecular Biology Inc.卷 / 296期
基金
美国国家卫生研究院;
关键词
Cell proliferation;
D O I
10.1016/J.JBC.2021.100739
中图分类号
学科分类号
摘要
Insulin-like growth factor (IGF) is a potent mitogen that activates the IGF receptor (IGFR)/insulin receptor substrate (IRS) axis, thus stimulating growth in normal cells and uncontrolled cell proliferation in cancer. Posttranslational modifications of IRS such as ubiquitination tightly control IGF signaling, and we previously identified IRS-1 as a potential substrate for the E3 ubiquitin ligase TRAF4 using an unbiased screen. Here we provide evidence that TRAF4-mediated ubiquitination of IRS-1 is physiologically relevant and crucial for IGF signal transduction. Through site-directed mutagenesis we found that TRAF4 promotes an atypical K29-linked ubiquitination at the C-terminal end of IRS-1. Its depletion abolishes AKT and ERK phosphorylation downstream of IGF-1 and inhibits breast cancer cell proliferation. Overexpression of TRAF4 enhances IGF1-induced IGFR-IRS-1 interaction, IRS-1 tyrosine phosphorylation, and downstream effector protein activation, whereas mutation of IRS-1 ubiquitination sites completely abolishes these effects. Altogether, our studies demonstrate that nonproteolytic ubiquitination of IRS-1 is a key step in conveying IGF-1 stimulation from IGFR to IRS-1. © 2021 THE AUTHORS.
引用
收藏
相关论文
共 6 条
  • [1] PHB2 promotes SHIP2 ubiquitination via the E3 ligase NEDD4 to regulate AKT signaling in gastric cancer
    Xu, Liang
    Xiang, Wanying
    Yang, Jiezhen
    Gao, Jing
    Wang, Xinyue
    Meng, Li
    Ye, Kaihong
    Zhao, Xiao Hong
    Zhang, Xu Dong
    Jin, Lei
    Ye, Yan
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [2] The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis
    Shimizu, Kouhei
    Fukushima, Hidefumi
    Ogura, Kohei
    Lien, Evan C.
    Nihira, Naoe Taira
    Zhang, Jinfang
    North, Brian J.
    Guo, Ailan
    Nagashima, Katsuyuki
    Nakagawa, Tadashi
    Hoshikawa, Seira
    Watahiki, Asami
    Okabe, Koji
    Yamada, Aya
    Toker, Alex
    Asara, John M.
    Fukumoto, Satoshi
    Nakayama, Keiichi I.
    Nakayama, Keiko
    Inuzuka, Hiroyuki
    Wei, Wenyi
    SCIENCE SIGNALING, 2017, 10 (460)
  • [3] miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation
    Bandi, Venkateshwarlu
    Baluchamy, Sudhakar
    MEDICAL ONCOLOGY, 2017, 34 (08)
  • [4] miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation
    Venkateshwarlu Bandi
    Sudhakar Baluchamy
    Medical Oncology, 2017, 34
  • [5] The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant Pathway
    Wang, Fang
    Zhang, Ye
    Shen, Jianliang
    Yang, Bin
    Dai, Weiwei
    Yan, Junrong
    Maimouni, Sara
    Daguplo, Heineken Q.
    Coppola, Sara
    Gao, Yingtang
    Wang, Yijun
    Du, Zhi
    Peng, Kesong
    Liu, Hui
    Zhang, Qin
    Tang, Fei
    Wang, Peng
    Gao, Shenglan
    Wang, Yongbo
    Ding, Wen-Xing
    Guo, Grace
    Wang, Fengmei
    Zong, Wei-Xing
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 11 (05): : 1369 - 1385
  • [6] Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
    Li, Wei
    You, Liru
    Cooper, Jonathan
    Schiavon, Gaia
    Pepe-Caprio, Angela
    Zhou, Lu
    Ishii, Ryohei
    Giovannini, Marco
    Hanemann, C. Oliver
    Long, Stephen B.
    Erdjument-Bromage, Hediye
    Zhou, Pengbo
    Tempst, Paul
    Giancotti, Filippo G.
    CELL, 2010, 140 (04) : 477 - 490